Composition for preventing or treating lung cancer comprising antibody against CD66C and chemotherapeutic agent
A use of prevention or treatment of lung cancer including an antibody specifically recognizing CD66c in lung cancer or its antigen-binding fragment and a chemotherapeutic agent is provided.
1. A method of treating a lung cancer, comprising administering an anti-CD66c (Cluster of Differentiation 66c) antibody being specific to a lung adenocarcinoma or an antigen-binding fragment thereof, and a chemotherapeutic agent as effective agent, to a subject in need,
wherein the anti-CD66c antibody is an antibody produced by hybridoma cell deposited as an accession number of KCLRF-BP-00230, and
wherein the chemotherapeutic agent is paclitaxel.
2. The method of claim 1 , wherein the antigen-binding fragment is Fab, Fab′, F(ab′)2, scFv, (scFv)2, scFvFc or dsFv.
3. The method of claim 1 , wherein the lung cancer is lung adenocarcinoma, Squamous cell carcinoma of lung, epithelial lung cancer, small cell lung cancer or non-small cell lung cancer.
4. The method of claim 1 , wherein the anti-CD66c antibody and the chemotherapeutic agent are administered in a mixed formulation, or administered simultaneously or sequentially in single formulation.
5. The method of claim 1 , wherein the anti-CD66c antibody is formulated for oral administration and the chemotherapeutic agent is formulated for parenteral administration.
6. The method of claim 1 , wherein the anti-CD66c antibody is formulated for injectable administration.